SCHEMBL8344949

SCHEMBL8344949

Oc1c(-c2ccc(F)cc2)cc(Cl)c2cccnc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.60
LMNA P02545 6/20 0.60
MAPT P10636 6/20 0.60
HTT P42858 5/20 0.60
SMN1; SMN2 Q16637 5/20 0.60
TDP1 Q9NUW8 5/20 0.60
KMT2A Q03164 4/20 0.60
HSP90AA1 P07900 4/20 0.60
MMP14 P50281 3/20 0.60
MEN1 O00255 3/20 0.60
ALOX12 P18054 3/20 0.60
ALDH1A1 P00352 3/20 0.60
TP53 P04637 2/20 0.60
CYP3A4 P08684 2/20 0.60
ALOX15 P16050 2/20 0.60
SLC6A2 P23975 2/20 0.60
OPRK1 P41145 2/20 0.60
ALOX15B O15296 1/20 0.60
NR1I2 O75469 1/20 0.60
HTR1A P08908 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10027196 0.89 KDM4E (0.60) KDM4ELMNAMAPTHTTSMN1; SMN2
SCHEMBL4040903 0.88 KDM4E (0.64) KDM4ELMNAMAPTHTTSMN1; SMN2
SCHEMBL8344720 0.87 KDM4E (0.66) KDM4ELMNAMAPTHTTSMN1; SMN2
SCHEMBL19891758 0.87 PIK3CD (0.51) KDM4ELMNAMAPTHTTSMN1; SMN2
SCHEMBL10027197 0.86 KDM4E (0.57) KDM4ELMNAMAPTHTTSMN1; SMN2
SCHEMBL13300833 0.86 HSP90AA1 (0.60) KDM4ELMNAMAPTHTTSMN1; SMN2
SCHEMBL6427554 0.85 PIK3CD (0.50) KDM4ELMNAMAPTHTTSMN1; SMN2
SCHEMBL6051170 0.85 KDM4E (0.77) KDM4ELMNAMAPTHTTSMN1; SMN2
Hydrochloric Acid SCHEMBL4036925 0.84 KDM4E (0.62) KDM4ELMNAMAPTHTTSMN1; SMN2
SCHEMBL8344349 0.83 KDM4E (0.57) KDM4ELMNAMAPTHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression SIERRA SCIENCES, INC. (US) 2023-07-18 US disclosed
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression SIERRA SCIENCES, INC. (US) 2023-07-18 US disclosed
US-9302993-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2016-04-05 US disclosed
US-9302993-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2016-04-05 US disclosed
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-11-26 US disclosed
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-11-26 US disclosed
US-9169211-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2015-10-27 US disclosed
US-9169211-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2015-10-27 US disclosed
US-20150094334-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-04-02 US disclosed
US-20150094334-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-04-02 US disclosed
US-20150025108-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-01-22 US disclosed
US-8163760-B2 Use of pyridopyrimidine compounds in the treatment of gliomas PRANA BIOTECHNOLOGY LIMITED (AU) 2012-04-24 US disclosed
US-8163760-B2 Use of pyridopyrimidine compounds in the treatment of gliomas PRANA BIOTECHNOLOGY LIMITED (AU) 2012-04-24 US disclosed
US-20100069393-A1 METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME PRANA BIOTECHNOLOGY LIMITED (AU) 2010-03-18 US disclosed
US-20100069393-A1 METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME PRANA BIOTECHNOLOGY LIMITED (AU) 2010-03-18 US disclosed
US-7619091-B2 Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) PRANA BIOTECHNOLOGY LIMITED (AU) 2009-11-17 US disclosed
US-7619091-B2 Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) PRANA BIOTECHNOLOGY LIMITED (AU) 2009-11-17 US disclosed
US-20080161353-A1 8-Hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2008-07-03 US disclosed
US-20080161353-A1 8-Hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2008-07-03 US disclosed
WO-2004007461-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069393-A1 METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME MGMT, DHFR, IDH2 KDM4E 2823/4885LMNA 2250/4885MAPT 1067/4885
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PARK7, COQ8A, NLN KDM4E 3604/4885LMNA 1440/4885MAPT 170/4885
US-20080161353-A1 8-Hydroxy quinoline derivatives PARK7, COQ8A, NLN KDM4E 3604/4885LMNA 1440/4885MAPT 170/4885
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression TERT, TERF2, RNGTT KDM4E 1300/4885LMNA 1682/4885MAPT 2505/4885
US-20150025108-A1 8-HYDROXY QUINOLINE DERIVATIVES PARK7, COQ8A, NLN KDM4E 3604/4885LMNA 1440/4885MAPT 170/4885
US-20150094334-A1 8-HYDROXY QUINOLINE DERIVATIVES PARK7, COQ8A, NLN KDM4E 3604/4885LMNA 1440/4885MAPT 170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.